Invokana & Brintellix are Spending the Most in Print Medical Journal Advertising

by Client Services

Invokana continues to be the drug product most advertised in medical journals in 2014. Through May, this drug, which treats type 2 Diabetes, has spent the most in advertising and purchased the highest number of ad pages, according to Kantar Media. Brintellix, an antidepressant, ranks second by both dollars and pages. Xarelto, which ranked first at this time in 2013, now ranks fourth.

Top 5 Print Ad Drugs (Dollars): May 2014

#1 Invokana – $9 MM (+251%)

#2 Brintellix Tablets– $6 MM (N/A)

#3 Fetzima - $5 MM (N/A)

#4 Xarelto - $4 MM (-52%)

#5 Belviq (Lorcaserin HCI) IV – $3 MM (N/A)

The percentage changes compare May 2014 to that same time period in 2013. For more information on these ad insights or other data, let one of us know.

Kantar Media sets the standard for accurate, comprehensive competitive advertising intelligence in the professional healthcare arena. Check back next month for updated data on the top products, classes, companies and category movers year-to-date.